Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/23/2025

Management of Barrett's Esophagus

Initial Patient Consultation and Education

  • The National Institute for Health and Care Excellence (NICE) recommends offering a clinical consultation immediately after diagnosis to discuss cancer risk and surveillance plans, with an annual rate of progression to adenocarcinoma of approximately 0.2-0.5% 1
  • Provide both verbal and written information about the diagnosis, treatment options, and patient support groups, allowing time for shared decision-making, as recommended by the guideline society 1, 3

Symptom Control and Medical Management

  • The National Institute for Health and Care Excellence (NICE) guidelines for GERD recommend managing gastroesophageal reflux symptoms using proton pump inhibitors as first-line therapy 1, 4
  • Do not offer aspirin specifically to prevent progression to dysplasia or cancer, as recommended by the guideline society 1, 3
  • Do not offer anti-reflux surgery to prevent progression to dysplasia or cancer, as it is not more effective than medical therapy, according to the guideline society 2, 4

Endoscopic Surveillance Protocol

  • Use high-resolution white light endoscopy with Seattle biopsy protocol (four-quadrant biopsies every 2 cm throughout the Barrett's segment), as recommended by the guideline society 1, 2
  • Ensure the benefits of surveillance outweigh risks based on the patient's overall health status, as recommended by the guideline society 1

Surveillance Intervals Based on Dysplasia Status

  • For non-dysplastic Barrett's esophagus, perform surveillance endoscopy every 3-5 years, as recommended by the guideline society 1
  • For indefinite for dysplasia, consider endoscopic surveillance at 6-month intervals with dose optimization of acid-suppressant medication, as recommended by the guideline society 2, 5
  • For low-grade dysplasia, confirm diagnosis with biopsy samples from two separate endoscopies, verified by two gastrointestinal pathologists, and offer radiofrequency ablation once confirmed, as recommended by the guideline society 1, 2, 5
  • For high-grade dysplasia, offer endoscopic resection of visible lesions as first-line treatment, and offer endoscopic ablation of any residual Barrett's esophagus after endoscopic resection, as recommended by the guideline society 1, 2, 5

Management of Stage 1 Adenocarcinoma

  • For T1a adenocarcinoma, offer endoscopic resection as first-line treatment, and follow with endoscopic ablation of residual Barrett's tissue, as recommended by the guideline society 2, 5
  • For T1b adenocarcinoma, offer oesophagectomy for patients fit for surgery with high-risk features, and consider radiotherapy alone or combined with chemotherapy for patients unfit for surgery, as recommended by the guideline society 2, 5
  • Consider endoscopic ultrasound for nodal staging based on endoscopic appearances or histological examination, as recommended by the guideline society 1, 5

Critical Pathology Confirmation

  • Ensure all dysplasia diagnoses are confirmed by at least two expert gastrointestinal pathologists to avoid unnecessary interventions, as recommended by the guideline society 5

Common Pitfalls to Avoid

  • Do not use CT before endoscopic resection for staging suspected T1 adenocarcinoma, as recommended by the guideline society 1, 5
  • Do not use endoscopic ultrasonography before endoscopic resection for staging suspected T1a adenocarcinoma, as recommended by the guideline society 1
  • Avoid recommending aspirin or anti-reflux surgery specifically for cancer prevention, as evidence does not support these interventions, as recommended by the guideline society 1, 3, 4